8-K: NeuroPace Announces Strong Preliminary 2024 Revenue and Board Appointment

NeuroPace reports preliminary unaudited revenue exceeding expectations for 2024 and appoints a new director to its board.

Summary

• NeuroPace has released preliminary unaudited revenue figures for the fourth quarter and full year 2024.
• The company expects Q4 revenue to be between $21.0 million and $21.5 million, representing a 17% to 19% increase compared to Q4 2023.
• Full-year 2024 revenue is projected to be between $79.4 million and $79.9 million, a 21% to 22% increase year-over-year.
• These preliminary results surpass the initial 2024 revenue guidance of $73 million to $77 million.
• As of December 31, 2024, NeuroPace anticipates having $52.8 million in cash and short-term investments and 30,145,039 shares of common stock outstanding.
• The company's NAUTILUS pivotal trial is on track to complete the one-year follow-up in March 2025, with data analysis starting in the second quarter of 2025.
• Scott Huennekens has been appointed to the Board of Directors, effective January 6, 2025.
• NeuroPace will present at the J.P. Morgan Healthcare Conference on January 15, 2025, and host an Investor Day on January 28, 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, exceeding guidance, and the appointment of an experienced board member. The progress of the NAUTILUS trial is also a positive indicator. However, the results are preliminary and subject to change.

Positives

• NeuroPace's preliminary revenue for both Q4 and full-year 2024 exceeded initial guidance.
• The company experienced strong revenue growth of over 20% for the full year 2024.
• The NAUTILUS pivotal trial is progressing as planned.
• The appointment of Scott Huennekens to the board brings significant experience in the medical device industry.
• The company is actively engaging with investors through upcoming conferences and an Investor Day.

Negatives

• The financial results are preliminary and unaudited, subject to potential adjustments.
• The company's actual results may differ from these estimates due to the completion of year-end closing and auditing procedures.

Risks

• Actual operating results may differ significantly from the preliminary guidance provided.
• There are uncertainties related to market acceptance and adoption of NeuroPace's RNS System.
• Risks exist related to the pricing of the RNS System and the availability of adequate reimbursement.
• Regulatory compliance and approvals to expand the market for the RNS System pose potential risks.
• The company's future performance is subject to various factors outlined in their SEC filings.

Future Outlook

NeuroPace is focused on expanding access to and adoption of its RNS therapy and is continuing to execute its three-part growth strategy. The company is also progressing with the NAUTILUS pivotal trial and plans to release full financial results in early March 2025.

Management Comments

• Joel Becker, NeuroPace President and CEO, stated that the team did an excellent job executing on their strategy, resulting in 2024 revenue growth of more than 20%, strong gross margin performance, and reduced cash burn.
• Frank Fischer, NeuroPace Chairman of the Board, expressed excitement about Scott Huennekens joining the board to support the company's management team.
• Scott Huennekens stated he is excited by the opportunity to join the NeuroPace board and support the company's ongoing growth initiatives.

Industry Context

NeuroPace's announcement comes amid growing interest in medical device companies focused on neurological disorders. The company's focus on epilepsy treatment aligns with the increasing demand for innovative solutions in this area. The appointment of a seasoned executive like Scott Huennekens also signals a commitment to strategic growth and value creation.

Comparison to Industry Standards

• NeuroPace's revenue growth of 21-22% for the full year 2024 is strong compared to many medical device companies, especially those in the neurotechnology space.
• Companies like Medtronic (MDT) and Abbott (ABT), while much larger, serve as benchmarks in the medical device industry, and NeuroPace's growth rate is competitive with smaller, high-growth companies in the sector.
• The successful progression of the NAUTILUS trial is also a positive sign, as clinical trial progress is a key indicator of future potential for medical device companies.
• The appointment of Scott Huennekens, who has a track record of success with companies like Volcano Corporation, is a positive signal for investors.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and the appointment of an experienced board member.
• Employees may be motivated by the company's positive performance and growth prospects.
• Customers (patients and healthcare providers) may benefit from the continued development and availability of the RNS System.
• Suppliers and creditors may view the company as a stable and growing business partner.

Next Steps

• NeuroPace will release its full fourth quarter and full year 2024 financial results in early March 2025.
• The company will present at the J.P. Morgan Healthcare Conference on January 15, 2025.
• NeuroPace will host an Investor Day on January 28, 2025.
• The NAUTILUS pivotal trial is expected to complete the one-year follow-up in March 2025, with data analysis commencing in Q2 2025.

Key Dates

Keywords

NeuroPace, RNS System, Epilepsy, Medical Device, Revenue, Board of Directors, NAUTILUS Trial, Financial Results, Scott Huennekens, Investor Day